Citation

Zhang S, Dissanayaka NN, Dawson A, O'Sullivan JD, Mosley P, Hall W, Carter A. Int. Psychogeriatr. 2016; 28(10): 1597-1614.

Affiliation

UQ Centre for Clinical Research,The University of Queensland,Queensland,Australia.

Copyright

(Copyright © 2016, Cambridge University Press)

DOI

10.1017/S104161021600096X

PMID

27373317

Abstract

BACKGROUND: Impulse control disorders (ICDs) have become a widely recognized non-motor complication of Parkinson's disease (PD) in patients taking dopamine replacement therapy (DRT). There are no current evidence-based recommendations for their treatment, other than reducing their dopaminergic medication.

METHODS: This study reviews the current literature of the treatment of ICDs including pharmacological treatments, deep brain stimulation, and psychotherapeutic interventions.

RESULTS: Dopamine agonist withdrawal is the most common and effective treatment, but may lead to an aversive withdrawal syndrome or motor symptom degeneration in some individuals. There is insufficient evidence for all other pharmacological treatments in treating ICDs in PD, including amantadine, serotonin selective reuptake inhibitors, antipsychotics, anticonvulsants, and opioid antagonists (e.g. naltrexone). Large randomized control trials need to be performed before these drugs can be routinely used for the treatment of ICDs in PD. Deep brain stimulation remains equivocal because ICD symptoms resolve in some patients after surgery but may appear de novo in others. Cognitive behavioral therapy has been shown to improve ICD symptoms in the only published study, although further research is urgently needed.

CONCLUSIONS: Further research will allow for the development of evidence-based guidelines for the management of ICDs in PD.

Language: en